contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


medcap-ab-growth-and-strong-earnings-ebitda-increased-by-39percent

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

MedCap operates in the investment industry and focuses on long-term equity investments in medical technology and pharmaceutical companies. The company's portfolio includes companies in sectors such as biotechnology and medical technology. The operations are primarily concentrated in Sweden, with a primary presence in the Stockholm region. MedCap was founded in 2001 and is headquartered in Stockholm.

MedCap

FIRST QUARTER, JANUARY-MARCHThe Group's net sales amounted to SEK 262.8 (222.6) million, an increase of 18 percent.The Group's EBITDA was SEK 56.3 (40.5) million, an increase of 39 percent.The...

FIRST QUARTER, JANUARY-MARCH<ul><li>The Group's net sales amounted to SEK 262.8 (222.6) million, an increase of 18 percent.</li><li>The Group's EBITDA was SEK 56.3 (40.5) million, an increase of 39 percent.</li><li>The EBITDA margin was 21 (18) percent.</li><li>Profit after tax amounted to SEK 19.7 (15.1) million.</li><li>Earnings per share amounted to SEK 1.3 (0.9).</li><li>Cash flow from operating activities was SEK 56.3 (17.3) million.</li></ul>CEO's commentsSales growthThe Group's sales increased by 18 percent in the first quarter. The Group's companies experienced good demand and both business areas showed good sales growth. In MedTech, sales increased for all companies. In Specialty Pharma, sales increased mainly in the registered pharmaceutical portfolio, but contract manufacturing also increased its sales.Margin improvementEBITDA increased by 39 percent. The EBITDA margin was 21 percent, an improvement of 3 percentage points. Higher volumes contributed to the increased margin. Purchasing and transport costs increased and have been partly offset by price increases. Delivery problems and long lead times are occurring for several inputs, but this has not had a significant impact on the Group as a whole.Strong financial position and capacity for acquisitionsMedCap is a long-term owner that acquires and develops small and medium-sized life science companies that are strong in a product area or market, and have potential for continuing expansion. The Group has a strong financial position and we see good opportunities for acquisitions.In conclusionThe horrific events in Ukraine are a humanitarian tragedy. The Group does not have any operations in Ukraine or Russia, but it is difficult to foresee what impact the invasion may have on international supply chains.The first quarter was a good start to the year for all the Group's companies. I see good opportunities for continued positive development.Anders Dahlberg, CEOStockholm, 6 May 2022This disclosure contains information that MedCap AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 06-05-2022 06:30 CET.